STOCK TITAN
  1. Home
  2. News
  3. AXNX

Axonics Inc - AXNX STOCK NEWS

Welcome to our dedicated news page for Axonics (Ticker: AXNX), a resource for investors and traders seeking the latest updates and insights on Axonics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axonics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axonics's position in the market.

News
Boston Scientific Announces Results for First Quarter 2024
Rhea-AI Summary
Boston Scientific (NYSE: BSX) reported strong financial results for the first quarter of 2024, with net sales of $3.856 billion, a 13.8% increase on a reported basis. The company achieved GAAP net income of $495 million, compared to $300 million a year ago, and an adjusted EPS of $0.56. Various business segments and regions showed growth, with significant developments in product launches, clinical trials, and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
earnings
-
News
Axonics Stockholders Approve Merger Agreement with Boston Scientific
Rhea-AI Summary
Axonics, Inc. (AXNX) stockholders vote to adopt merger agreement with Boston Scientific (BSX). The majority of shares voted in favor of the merger. The closing is expected in the first half of 2024, subject to certain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
acquisition
-
News
Axonics Provides Update on Inter Partes Review Proceedings
Rhea-AI Summary
Axonics, Inc. (Nasdaq: AXNX) announced that the PTAB invalidated 10 of the 15 challenged claims in Medtronic's '314 patent. The district court case with Medtronic is currently stayed. Axonics plans to seek review of the PTAB's finding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
News
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
Rhea-AI Summary
Axonics, Inc. (Nasdaq: AXNX) has received CE Mark approval for its Axonics R20™ rechargeable sacral neuromodulation system, offering a 20-year functional life and reduced recharging frequency. The device maintains a small form factor, enhanced programming capabilities, and expanded MRI labeling, aiming to improve patient experience and market expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
-
News
Axonics Responds to ITC Action by Medtronic
Rhea-AI Summary
Axonics (AXNX) faces legal action from Medtronic over patent infringement related to MRI compatibility for medical devices. Axonics CEO vows to defend vigorously and emphasizes innovation in sacral neuromodulation therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Rhea-AI Summary
Axonics, Inc. (AXNX) reported strong financial results for the fourth quarter and fiscal year ended December 31, 2023. Revenue grew 34% in 2023, reaching $366.4 million. The company generated over $50 million of adjusted EBITDA. Axonics therapies treated approximately 100,000 incontinence patients globally in 2023. Net revenue for Q4 2023 was $109.7 million, with a gross margin of 75.4%. Operating expenses were $81.7 million, with a net income of $6.6 million. Cash, cash equivalents, short-term investments, and restricted cash totaled $358 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
earnings
News
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
Rhea-AI Summary
Boston Scientific Corporation (NYSE: BSX) reported strong financial results for the fourth quarter and full year 2023, with net sales of $3.725 billion and $14.240 billion, respectively. The company achieved significant growth in net sales, GAAP net income, and adjusted EPS compared to the prior year period. The CEO, Mike Mahoney, expressed gratitude towards the global team for the exceptional results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
earnings
-
News
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
Rhea-AI Summary
Axonics, Inc. (AXNX) Reports Strong Revenue Growth in Q4 and FY23, Expects 27% and 34% Increases Respectively. Preliminary unaudited revenue for Q4 2023 is $109.3 to $109.7 million, an increase of 27% compared to the prior year period. Fiscal Year 2023 revenue is expected to be approximately $366.1 million, an increase of 34% compared to fiscal year 2022. The company attributes the growth to higher utilization and share of wallet at existing customers and the onboarding of new accounts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
earnings
-
News
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
Rhea-AI Summary
Axonics, Inc. (AXNX) has entered into a definitive agreement to be acquired by Boston Scientific Corporation (BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to the Boston Scientific Urology business and has pioneered significant enhancements to sacral neuromodulation therapy for bladder and bowel dysfunction and urethral bulking for women with stress urinary incontinence. The transaction is expected to close in the first half of 2024, pending approval of Axonics’ stockholders and receipt of required regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
acquisition
News
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
Rhea-AI Summary
Boston Scientific Corporation (BSX) to acquire Axonics, Inc. (AXNX) for $3.7 billion, expanding its urology portfolio with technologies to treat urinary and bowel dysfunction. Axonics' products include the Axonics R20TM and the Axonics F15TM Systems for sacral neuromodulation therapy, with expected high revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.48%
Tags
acquisition
Stock AXNX logo
Axonics Inc

NYSE:AXNX

AXNX Rankings

#1447 Ranked by Market Cap
#3982 Ranked by Stock Gains
N/A Ranked by Dividends

AXNX Stock Data

3.43B
50.43M
1.07%
103.05%
6.74%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Irvine

About AXNX

axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.